{"id":857,"date":"2013-01-11T07:53:00","date_gmt":"2013-01-11T07:53:00","guid":{"rendered":"\/?p=857"},"modified":"2013-03-25T20:14:44","modified_gmt":"2013-03-25T20:14:44","slug":"amarantus-bioscience-inc-otcambs-crushed-50-in-two-days","status":"publish","type":"post","link":"\/articles\/amarantus-bioscience-inc-otcambs-crushed-50-in-two-days\/","title":{"rendered":"Amarantus Bioscience, Inc. (OTC:AMBS) Crushed 50% in Two Days"},"content":{"rendered":"

\"99AMBS_chart.png\"After crashing over 27% on Wednesday, in yesterday’s session Amarantus Bioscience, Inc. (OTC:AMBS<\/a>) caved in another 28% down to a close of $0.069 per share. Just a week ago the stock was trading at $0.15. <\/p>\n

Over the last two and a half months AMBS<\/a> went from under a cent per share to peaks of $0.15. The company kept putting out news and reports about various aspects of its flagship product, the MANF protein that aims to deal with Parkinson’s. As the news rolled out, the stock price kept climbing, propped by some minor pump efforts as well as the optimistic news.<\/p>\n

However, in 2013 the stock teetered briefly on the edge, then started slipping back down to what may be a more realistic price for a company with next to no cash and a medical product in deep pre-clinical testing. As of the date of their latest quarterly report from September 2012, AMBS<\/a> had the following:<\/p>\n